Pre-market hot trades in US stocks: UPLD pre-market down 8.07%: Board member reduction in holdings combined with huge losses in financial reports, confidence shaken

Pre-market Hot Trades in US Stocks

Upland Software is down 8.07% in pre-market trading. Based on recent key news:

1. On August 6, Upland Software director Timothy Mattox sold 1,000 shares of common stock at a price of $4.27 per share. This raised concerns about internal confidence in the company, putting pressure on the stock price. Source: EDGAR system disclosure

2. On August 14, Upland Software's financial report showed an expanded net loss, with a net loss per share reaching $12.53, significantly increasing compared to the same period last year. Poor financial performance heightened investor concerns, leading to a decline in stock price. Source: Business Wire

3. No other significant news recently. The tech industry is facing profit pressure, with noticeable capital outflows.

Top Gainers in Pre-market US Stocks

WeBus is up 196.96% in pre-market trading. Based on recent key news:

1. On August 10, Wetour Robotics Ltd. released important information through the EDGAR system, possibly involving strategic adjustments or new product launches, leading to increased market expectations for future growth and a significant rise in stock price. Source: EDGAR

2. On August 11, market tolerance for traditional business models decreased, and investors expressed skepticism about the company's ability to achieve digital transformation. Nevertheless, there remains market anticipation for its AI labels and smart hardware, affecting stock price volatility. Source: Public Technologies

3. No other significant news recently. Market expectations for digital transformation have increased.

Capricor Therapeutics is up 80.29% in pre-market trading. Based on recent key news:

1. On August 14, Capricor Therapeutics announced that the US FDA agreed to review new data for its Duchenne muscular dystrophy therapy, causing the stock price to rise 116.9% in pre-market. The company plans to submit additional trial data showing improvements in upper limb muscle function. The FDA's review decision is expected before August 22. Source: Reuters

2. On August 14, Cantor analyst Kristen Kluska stated that the FDA's willingness to review new muscle data is "a very unexpected and potentially positive surprise," which reduces regulatory risk. Source: Reuters

3. On August 14, Capricor Therapeutics reported a net loss of $40.7 million for the second quarter, with cash and cash equivalents decreasing to $237.9 million. The stock price has fallen 85.4% year-to-date. Source: Reuters The biotechnology industry is currently facing regulatory uncertainty.

SurgePays is up 62.81% in pre-market trading. Based on recent key news:

1. On August 11, SurgePays entered potential joint venture negotiations with LowWeeklyPayments to expand its smartphone rental purchase program This move has boosted market optimism about the company's future growth, leading to a significant increase in stock prices. Source: Reuters

2. On August 14, SurgePays announced a net income of $1.29 million and revenue of $16.2 million for the second quarter. Strong financial performance has enhanced investor confidence, further driving up stock prices. Source: Reuters

3. On August 11, the company reported that retail sales of its smartphone rental purchase program reached $176,000 in July, a month-on-month increase of 23%. This growth demonstrates the potential of the company's business, attracting more investor attention. Source: Reuters The US stock market has recently experienced increased volatility, and risks need to be monitored